Argent Trust CO Bristol Myers Squibb CO Transaction History

Argent Trust CO

$2.39 Billion
Q3 2024

A detailed history of Argent Trust CO transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Argent Trust CO holds 71,814 shares of BMY stock, worth $4.15 Million. This represents 0.16% of its overall portfolio holdings.

Number of Shares

71,814

Previous 74,323 3.38%

Holding current value

$4.15 Million

Previous $3.09 Million 20.41%

% of portfolio

0.16%

Previous 0.14%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$39.66 - $51.75 $99,506 - $129,840	-2,509 Reduced 3.38%	71,814 $3.72 Million
Q2 2024 Aug 12, 2024	SELL	$40.25 - $52.99 $1.12 Million - $1.47 Million	-27,780 Reduced 27.21%	74,323 $3.09 Million
Q1 2024 May 10, 2024	SELL	$47.98 - $54.4 $252,566 - $286,361	-5,264 Reduced 4.9%	102,103 $5.54 Million
Q4 2023 Feb 09, 2024	BUY	$48.48 - $57.85 $53,667 - $64,039	1,107 Added 1.04%	107,367 $5.51 Million
Q3 2023 Nov 08, 2023	BUY	$57.89 - $64.73 $316,253 - $353,619	5,463 Added 5.42%	106,260 $6.17 Million
Q2 2023 Aug 11, 2023	BUY	$63.71 - $70.74 $109,772 - $121,885	1,723 Added 1.74%	100,797 $6.45 Million
Q1 2023 May 12, 2023	BUY	$65.71 - $74.53 $196,538 - $222,919	2,991 Added 3.11%	99,074 $6.87 Million
Q4 2022 Feb 10, 2023	SELL	$68.48 - $81.09 $165,584 - $196,075	-2,418 Reduced 2.45%	96,083 $6.91 Million
Q3 2022 Nov 10, 2022	BUY	$0.13 - $76.84 $251 - $148,685	1,935 Added 2.0%	98,501 $7 Million
Q2 2022 Aug 11, 2022	BUY	$72.62 - $79.98 $59,330 - $65,343	817 Added 0.85%	96,566 $7.44 Million
Q1 2022 May 11, 2022	SELL	$61.48 - $73.72 $469,584 - $563,073	-7,638 Reduced 7.39%	95,749 $6.99 Million
Q4 2021 Feb 09, 2022	BUY	$53.63 - $62.52 $333,524 - $388,811	6,219 Added 6.4%	103,387 $6.45 Million
Q3 2021 Nov 09, 2021	BUY	$59.17 - $69.31 $66,033 - $77,349	1,116 Added 1.16%	97,168 $5.75 Million
Q2 2021 Aug 09, 2021	BUY	$61.91 - $67.42 $71,072 - $77,398	1,148 Added 1.21%	96,052 $6.42 Million
Q1 2021 May 12, 2021	SELL	$59.34 - $66.74 $108,414 - $121,933	-1,827 Reduced 1.89%	94,904 $5.99 Million
Q4 2020 Feb 11, 2021	SELL	$57.74 - $65.43 $16,340 - $18,516	-283 Reduced 0.29%	96,731 $6 Million
Q3 2020 Nov 13, 2020	BUY	$57.43 - $63.64 $566,317 - $627,554	9,861 Added 11.31%	97,014 $5.85 Million
Q2 2020 Aug 04, 2020	BUY	$54.82 - $64.09 $389,770 - $455,679	7,110 Added 8.88%	87,153 $5.13 Million
Q1 2020 May 11, 2020	SELL	$46.4 - $67.43 $12,481 - $18,138	-269 Reduced 0.33%	80,043 $4.46 Million
Q4 2019 Feb 11, 2020	BUY	$49.21 - $64.19 $739,970 - $965,225	15,037 Added 23.04%	80,312 $5.16 Million
Q3 2019 Nov 12, 2019	SELL	$42.77 - $50.71 $48,458 - $57,454	-1,133 Reduced 1.71%	65,275 $3.31 Million
Q2 2019 Aug 13, 2019	SELL	$44.62 - $49.34 $4,149 - $4,588	-93 Reduced 0.14%	66,408 $3.01 Million
Q1 2019 May 15, 2019	SELL	$45.12 - $53.8 $125,975 - $150,209	-2,792 Reduced 4.03%	66,501 $3.17 Million
Q4 2018 Feb 06, 2019	SELL	$48.76 - $63.23 $261,792 - $339,481	-5,369 Reduced 7.19%	69,293 $3.6 Million
Q3 2018 Nov 14, 2018	BUY	$55.19 - $62.25 $39,957 - $45,069	724 Added 0.98%	74,662 $4.59 Million
Q2 2018 Apr 15, 2019	BUY	$50.53 - $62.98 $59,372 - $74,001	1,175 Added 1.61%	73,938 $4.09 Million
Q2 2018 Aug 15, 2018	BUY	$50.53 - $62.98 $2.94 Million - $3.67 Million	58,231 Added 400.71%	72,763 $4.03 Million
Q1 2018 May 15, 2018	BUY	$59.92 - $68.98 $328,960 - $378,700	5,490 Added 60.72%	14,532 $919,000
Q4 2017 Feb 12, 2018	SELL	$59.94 - $65.35 $33,626 - $36,661	-561 Reduced 5.84%	9,042 $554,000
Q3 2017 Nov 13, 2017	BUY	$55.23 - $63.74 $530,373 - $612,095	9,603	9,603 $612,000

Others Institutions Holding BMY

# of Institutions

2,536

Shares Held

1.47B

Call Options Held

31.6M

Put Options Held

35M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $123B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Argent Trust CO, based on Form 13F filings with the SEC.

News

Stay updated on Argent Trust CO with notifications on news.

Account